Authors’ reply: PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer?

Ian Alberts*, Svenja Elizabeth Seide, Clemens Mingels, Karl Peter Bohn, Kuangyu Shi, Helle D. Zacho, Axel Rominger, Ali Afshar-Oromieh

*Corresponding author for this work

Research output: Contribution to journalComment/debateResearchpeer-review

Original languageEnglish
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume48
Issue number8
Pages (from-to)2307–2308
Number of pages2
ISSN1619-7070
DOIs
Publication statusPublished - Jul 2021

Keywords

  • Glutamate Carboxypeptidase II
  • Humans
  • Male
  • Positron-Emission Tomography
  • Prostatic Neoplasms/diagnostic imaging
  • Radiopharmaceuticals

Cite this